Abstract
Background: Recently, our research team developed an open source and free website called the MEPP website (for the Mirror Effect Plus Protocol) to efficiently provide mirror therapy for patients with facial palsy. Previous studies demonstrated that the first version of the MEPP website improved user experience and likely optimized patients’ performance during facial therapy. Nevertheless, compliance was found to be low despite a generally positive opinion of the website, and in light of our earlier findings, MEPP 2.0—a revised and enhanced version of the MEPP 0.1—was created. The purpose of this study was to examine and contrast various factors that help or impede institutional partners of the Quebec health care system from using the MEPP 2.0 website in comparison to its initial version.
Methods: Forty-one patients with facial palsyand nineteen clinicians working with this population were enrolled in a within-subject crossover study. For both the MEPP 1.0 and MEPP 2.0, user experience was assessed for all participants. Embodiment was assessed in patients, and factors influencing clinical use were assessed by clinicians. Qualitative comments about their experiences were also gathered. Descriptive statistics and reliability measures were calculated. Differences between the two MEPP versions were assessed using the linear mixed model.
Results: Overall, patients appreciated more the MEPP 2.0 (OR = 4.57; p < 0.001), and all clinicians preferred the MEPP 2.0 over the MEPP 1.0. For patients, it seems that facial ownership, as well as possession and control of facial movements, was significantly better with the MEPP 2.0. For clinicians, the MEPP 2.0 specifically allowed them to self-evaluate their intervention and follow up with more objectivity. The use of the MEPP 2.0 was also modulated by what their patients reported. Qualitatively, options to access an Android app and needs for improving the exercises bank were mentioned as hindering factors.
Conclusions: The updated version of the MEPP website, the MEPP 2.0, was preferred by our different partners.
Trial registration:
https://www.isrctn.com/ISRCTN10885397
The trial was registered before the start of the study on the 1st December 2023